Validation of the 96 well Caco-2 cell culture model for high throughput permeability assessment of discovery compounds

被引:74
作者
Marino, AM
Yarde, M
Patel, H
Chong, SH
Balimane, PV [1 ]
机构
[1] Bristol Myers Squibb Co, Metab & Pharmacokinet, Princeton, NJ USA
[2] Bristol Myers Squibb Co, Lead Discovery Profiling, Princeton, NJ USA
关键词
permeability; Caco-2; cells; high throughput screening; absorption; transport; drug discovery;
D O I
10.1016/j.ijpharm.2005.03.008
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The use of Caco-2 cells for permeability screening of discovery compounds is quite well established and serves as the "method-of-choice" across the pharmaceutical industries worldwide. The typical permeability-screening model involves growing cells on a 12 well or 24 well transwell format. In this manuscript, we report the use of Caco-2 cells grown on 96 well transwell plates for screening of discovery compounds to assess their permeability characteristics. A set of standard compounds (marketed compounds) belonging to the various class of Biopharmaceutics Classification System (BCS) were used to assess the utility of the 96 well Caco-2 cells. Extensive validations were also performed with similar to 160 Bristol-Myers Squibb (BMS) discovery compounds by comparing the permeability values in the 96 well Caco-2 cells with the in-house 24 well Caco-2 cells. Functional Caco-2 cells with intact monolayers could be established in the 96 well format using optimized seeding and culturing conditions. The permeability of BCS compounds in the 96 well format was found to be comparable to the permeability in 24 well format. Similarly, there was very good correlation (R-2 = 0.93) between the two formats for the extensive validation performed with in-house discovery Compounds. The validated 96 well Caco-2 cell system presents a very attractive permeability screening tool that can perform much more efficiently than the conventional 12 well or 24 well systems while providing the same high quality permeability screening data. (c) 2005 Elsevier B.V. All rights reserved.
引用
收藏
页码:235 / 241
页数:7
相关论文
共 24 条
[1]   Development of a 7-day, 96-well Caco-2 permeability assay with high-throughput direct UV compound analysis [J].
Alsenz, J ;
Haenel, E .
PHARMACEUTICAL RESEARCH, 2003, 20 (12) :1961-1969
[2]   Intestinal drug absorption and metabolism in cell cultures: Caco-2 and beyond [J].
Artursson, P ;
Borchardt, RT .
PHARMACEUTICAL RESEARCH, 1997, 14 (12) :1655-1658
[3]   CORRELATION BETWEEN ORAL-DRUG ABSORPTION IN HUMANS AND APPARENT DRUG PERMEABILITY COEFFICIENTS IN HUMAN INTESTINAL EPITHELIAL (CACO-2) CELLS [J].
ARTURSSON, P ;
KARLSSON, J .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1991, 175 (03) :880-885
[4]  
ARTURSSON P, 1991, CRIT REV THER DRUG, V8, P305
[5]  
Avdeef Alex, 2001, Current Topics in Medicinal Chemistry, V1, P277, DOI 10.2174/1568026013395100
[6]   Utility of 96 well Caco-2 cell system for increased throughput of P-gp screening in drug discovery [J].
Balimane, PV ;
Patel, K ;
Marino, A ;
Chong, SH .
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2004, 58 (01) :99-105
[7]   Current methodologies used for evaluation of intestinal permeability and absorption [J].
Balimane, PV ;
Chong, SH ;
Morrison, RA .
JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS, 2000, 44 (01) :301-312
[8]   THE MADIN DARBY CANINE KIDNEY (MDCK) EPITHELIAL-CELL MONOLAYER AS A MODEL CELLULAR-TRANSPORT BARRIER [J].
CHO, MJ ;
THOMPSON, DP ;
CRAMER, CT ;
VIDMAR, TJ ;
SCIESZKA, JF .
PHARMACEUTICAL RESEARCH, 1989, 6 (01) :71-77
[9]   In vitro permeability through Caco-2 cells is not quantitatively predictive of in vivo absorption for peptide-like drugs absorbed via the dipeptide transporter system [J].
Chong, SH ;
Dando, SA ;
Soucek, KM ;
Morrison, RA .
PHARMACEUTICAL RESEARCH, 1996, 13 (01) :120-123
[10]  
Collett A, 1999, J PHARMACOL EXP THER, V288, P171